NCT03885830View on ClinicalTrials.gov

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
CML, Chronic PhaseCML (Chronic Myelogenous LeukemiaCML - Philadelphia ChromosomeChronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Interventions
DRUG

Bosutinib

Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.

DRUG

Dasatinib

Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.

DRUG

Imatinib

Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.

DRUG

Nilotinib

Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.

Trial Locations (1)

27514

UNC Hospital, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | Biotech Hunter | Biotech Hunter